McKeage, Kate; Plosker, Greg L. - In: PharmacoEconomics 26 (2008) 3, pp. 251-268
Zoledronic acid (Zometa(R)) is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM). In patients with advanced breast or prostate cancer, zoledronic acid...